Differences in some behavioural effects of deprenyl and amphetamine enantiomers in rats

Physiology and Behavior

Volumn 60, Issue 2, 1996, Pages 581-587

  Timár, Julia ^a   Gyarmati, Zsuzsanna ^b   Barna, Láazló ^b   Knoll, Bertha ^b  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b NONE

Author keywords

( ) Deprenyl; Amphetamine enantiomers; Behavioural differences; Deprenyl enantiomers

Indexed keywords

AMPHETAMINE; SELEGILINE;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR; CONDITIONING; ENANTIOMER; FEMALE; HEAD MOVEMENT; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY;

EID: 0030220545     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/0031-9384(96)00069-8     Document Type: Article

References (33)

1. 1. Birkmayer, W.; Riederer, P.; Linauer, W.; Knoll, J. L-deprenyl plus l-phenylalanine in the treatment of depression. J. Neural Transm. 59:81-87; 1984.
2. 2. Butcher, S. P.; Fairbrother, I. S.; Kelly, J. S.; Arbuthnott, G. W. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J. Neurochem. 55:981-988; 1990.
3. 3 receptor antagonists block morphine-and nicotine-but not amphetamine-induced reward. Psychopharmacology (Berlin) 97:175-178; 1989.
4. 4. Elsworth, J. D.; Sandier, M.; Lees, A. J.; Ward, C.; Stern, G. M. The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties. J. Neural Transm. 54:105-110; 1982.
5. 5. Engberg, G.; Elebring, T.; Nissbrandt, H. Deprenyl (Selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J. Pharmacol. Exp. Ther. 259:841-847; 1991.
6. 11C-labeled suicide inactivators and PET. Science 235: 481-485; 1987.
7. 7. Heinonen, E. H.; Myllylä, V.; Sotaniemi, K.; Lamintausta, R.; Salonen, J. S.; Antilla, M.; Savijärvi, M.; Kotila, M.; Rinne, U. K. Pharmacokinetics and metabolism of selegiline. Acta Neurol. Scand. 126:93-99; 1989.
8. 8. Inoue, O.; Axelsson, S.; Lundquist, H.; Oreland, L.; Langström, B. Effect of reserpine on the brain uptake of carbon 11 methamphetamine and its N-propargyl derivative, deprenyl. Eur. J. Nucl. Med. 17:121-126; 1990.
9. 9. Kalász, H.; Kerecsen, L.; Knoll, J.; Pucsok, J.; Dobó, R.; Hollósi, I. Studies on the metabolism of (-)-deprenyl by gas chromatography mass spectrometry. In: Kalász, H.; Ettre. L. S., eds. Chromatography, 87. Budapest: Akadémiai Kiadó, 1988:275-283.
10. 10. Karoum, F.; Chuang, L. W.; Eisler, T.; Calne, D. B.; Liebowitz, M. R.; Quitkin, F. M.; Klein, D. F.; Wyatt, R. J. Metabolism of (-)-deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: A biochemical assessment. Neurology 32:503-509; 1982.
11. 11. Knoll, J. Deprenyl (selegiline): The history of its development and pharmacological action. Acta Neurol. Scand. Suppl. 95:57-80; 1983.
12. 12. Knoll, J. The enantioselective pharmacological spectrum of levo (-)-deprenyl. In: Simonyi, M., ed. Problems and wonders of chiral molecules. Budapest: Akadémiai Kiadó; 1990:255-265.
13. 13. Knoll, J. The pharmacological basis of the beneficial effects of (-)-deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J. Neural Transm. Suppl. 40:69-91; 1993.
14. 14. Knoll, J. Memories of my 45 years in research. Pharmacol. Toxicol. 75:65-72; 1994.
15. 15. Knoll, J.; Ecseri, Z.; Kelemen, K.; Nievel, J.; Knoll, B. Phenylisopropylmethylpropinylamine (E-250): A new spectrum psychic energizer. Arch. Int. Pharmacodyn. Ther. 155:154-164; 1965.
16. 16. Knoll, J.; Magyar, K. Some puzzling effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5:393-408; 1972.
17. 17. Knoll, J.; Miklya, I. Multiple, small dose administration of (-)-deprenyl enhances catecholaminergic activity and diminishes serotonergic activity in the brain and these effects are unraleted to MAO-B inhibition. Arch. Int. Pharmacodyn. Ther. 328:1-15; 1994.
18. 18. Magyar, K.; Vizi, E. S.; Ecseri, Z.; Knoll, J. Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol. Hung. 32:377-387; 1967.
19. 19. Magyar, K.; Tóthfalusi, L. Pharmacokinetic aspects of deprenyl effects. Pol. J. Pharmacol. Pharm. 36:373-384; 1984.
20. 20. Mangoni, A.; Grassi, M. P.; Frattola, L.; Piolti, R.; Bassi, S.; Motta, A.; Marcone, A.; Smirne, S. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur. Neurol. 31:100-107; 1991.
21. 21. Mann, J. J.; Aarons, S. F.; Wilner, P. J.; Keil, P. G.; Sweeney, J. A.; Pearlstein, T.; Frances, A. J.; Kocsis, J. H.; Brown, R. P. A controlled study of the antidepressant efficacy and side effects of (-) -deprenyl. Arch. Gen. Psychiatry 46:45-50; 1989.
22. 22. Nickel, B.; Schulze, G.; Szelenyi, I. Effect of enantiomers of deprenyl (selegiline) and amphetamine on physical abuse liability and cortical electrical activity in rats. Neuropharmacology 29:983-992; 1990.
23. 23. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:176-183; 1993.
24. 24. Reynolds, G. P.; Elsworth, J. D.; Blau, K.; Sandler, M.; Lees, A. J.; Stern, G. M. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 6:542-544; 1978.
25. 25. Robinson, J. B. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Biochem. Pharmacol. 34:4105-4108; 1985.
26. 26. Schachter, M.; Marsden, C. D.; Parkes, J. D.; Jenner, P.; Testa, B. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J. Neurol. Neurosurg. Psychiatry 43:1016-1021; 1980.
27. 27. Stern, G. M.; Lees, A. J.; Hardie, R. J.; Sandler, M. Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease. Mod. Prob. Pharmacopsychiatry 19:215-219; 1983.
28. 28. Tariot, P. N.; Cohen, R. M.; Sunderland, T.; Newhouse, P. A.; Yount, D.; Mellow, A. M.; Weingartner, H.; Mueller, E. A.; Murphy. D. L. L(-)-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch. Gen. Psychiatry 44:427-433; 1987.
29. 29. Timár, J.; Knoll, B.; Knoll. J. Long-term administration of (-)-deprenyl (selegiline), a compound which facilitates dopaminergic tone in the brain, leaves the sensitivity of dopamine receptors to apomorphine unchanged. Arch. Int. Pharmacodyn. Ther. 284:255-266; 1986.
30. 30. Timár, J.; Knoll, B.; Knoll, J. (-)-Deprenyl (Selegiline) is devoid of amphetamine-like behavioural effects in rats. Acta Physiol. Hung. 79:131-137; 1992.
31. 31. Yasar, S.; Winger, G.; Nickel, B.; Schulze, G.; Goldberg, S. R. Preclinical evaluation of 1(-)-deprenyl: Lack of amphetamine-like abuse potential. In: Szelenyi, I., ed. Inhibitors of monoamine oxidase B, pharmacology and clinical use in neurodegenerative disorders. Basel: Birkhäuser Verlag; 1993:215-233.
32. 32. Yoshida, T.; Yamada, Y.; Yamamoto, T.; Kuroiwa, Y. Metabolism of deprenyl, a selective monoamine oxidase (MAO)B inhibitor in rat: Relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 16:129-136; 1986.
33. 33. Zsilla, G.; Knoll, J. The action of (-)-deprenyl on monoamine turn-over rate in rat brain. In: Costa, E.; Racagni, G., eds. Typical and atypical antidepressants: Molecular mechanisms. New York: Raven Press; 1982:211-217.